Omega Advisors’s Acceleron Pharma XLRN Stock Holding History

Omega Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,000	Closed	-$1.76M	–	105
2018 Q1	$1.76M	Sell	45,000 -5,000	-10%	-$213K	0.07%	78
2017 Q4	$2.12M	Hold	50,000	–	–	0.08%	62
2017 Q3	$1.87M	Buy	+50,000	New	+$1.74M	0.07%	75

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Omega Advisors's XLRN Position: Q2 2018 in Review

Omega Advisors sold out of Acceleron Pharma (XLRN) in Q2 2018, closing a stake of 45,000 shares — an estimated $1.76M sold.

Omega Advisors first reported a position in XLRN in Q3 2017 and held it in 3 quarters. The position peaked at $2.12M in Q4 2017. 170 funds tracked by Wall St. Rank hold XLRN as of Q2 2018.

Omega Advisors reported no remaining Acceleron Pharma position as of Q2 2018 after selling out during the quarter.
Omega Advisors sold 45,000 Acceleron Pharma shares in Q2 2018, an estimated $1.76M.
Omega Advisors first reported a position in Acceleron Pharma in Q3 2017 and held it in 3 quarters.
Omega Advisors's Acceleron Pharma position peaked at $2.12M in Q4 2017.
170 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2018.

Based on Omega Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.